Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-14. (Canceled)

15. (Currently amended): ~~A~~ The synthesized peptide ~~comprising the sequence SEQ ID NO:11~~ according to claim 35, wherein the peptide is ~~N-terminal is~~ N-terminally acetylated, or the peptide is ~~C-terminal is~~ C-terminally amidated, or both ~~the N-terminal is~~ N-terminally acetylated and ~~the C-terminal is~~ C-terminally amidated.

16. (Previously presented): An osteogenetic accelerator comprising the peptide set forth in claim 15, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier.

17. (Previously presented): The osteogenetic accelerator according to claim 16, wherein the carrier is selected from a group consisting of a ceramic, an artificial bone, a covalently cross-linked gel of alginate, and a gel of collagen, hyaluronic acid, calcium sulfate, polylactic acid, polyglycolic acid, hydroxyapatite, tricalcium phosphate, starch, chitin/chitosan, agarose, or dextran.

18. (Currently amended): ~~The~~ An osteogenetic accelerator ~~according to claim 16~~ comprising a synthesized peptide consisting of the SEQ ID NO: 11, wherein the peptide is N-terminally acetylated, or the peptide is C-terminally amidated, or both N-terminally acetylated and C-terminally amidated, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier, which contains 0.01 to 50 parts by weight of the peptide per 100 parts by weight of the carrier.

19. (Previously presented): An osteogenetic accelerator comprising the peptide of claim 15, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent.

20. (Currently amended): ~~The~~ An osteogenetic accelerator ~~according to claim 19~~ comprising a synthesized peptide consisting of the SEQ ID NO: 11, wherein the peptide is N-terminally acetylated, or the peptide is C-terminally amidated, or both N-terminally acetylated and C-terminally amidated, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent, wherein the aqueous solvent is physiological saline solution or a physiologically acceptable aqueous solution selected from a group consisting of mannitol, sucrose, lactose, maltose, glucose, and fructose.

21. (Currently amended): The osteogenetic accelerator according to claim ~~19 or~~ 20, wherein the concentration of the peptide is 0.001% to 5% with respect to the aqueous solvent.

22. (Previously presented): The osteogenetic accelerator as set forth in claim 16 which is used for treating a bone fracture by inducing bone formation at the fracture site or for inhibiting a decrease in bone substance.

23. (Canceled)

24. (Previously presented): An osteogenetic accelerator comprising a physiologically acceptable salt of the peptide set forth in claim 15.

25-34. (Canceled)

35. (Previously presented): A synthesized peptide consisting of the sequence SEQ ID NO:11.

36. (New): An osteogenetic accelerator comprising a synthesized peptide consisting of the SEQ ID NO: 11, wherein the peptide is N-terminally acetylated, or the peptide is C-terminally amidated, or both N-terminally acetylated and C-terminally amidated, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent, wherein the concentration of the peptide is 0.001% to 5% with respect to the aqueous solvent.